
Madrid-based pharmaceutical group Zeltia has reported strong results for the year ending 31 December 2010.
The group’s net revenues for 2010 totalled €153.5 million, a rise of 24.4 per cent from 2009, when revenues were €123.4 million. Zeltia said the increase was largely due to a 70 per cent growth in sales of Yondelis, Spain’s first anti-tumour drug.
At year-end, Yondelis had been approved for sale in 63 countries, 33 of which are outside the European Economic Area.




CasinosAUSTRIA_MAR11_emea_BROCH_s.pdf



